Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways  

作　　者：Akash Bararia Amlan Das Sangeeta Mitra Sudeep Banerjee Aniruddha Chatterjee Nilabja Sikdar 

机构地区：[1]Human Genetics Unit,Indian Statistical Institute,Kolkata 700108,India [2]Department of Biochemistry,Royal Global University,Assam 781035,India [3]Department of Biochemistry and Biophysics,University of Kalyani,West Bengal 741235,India [4]Department of Gastrointestinal Surgery,Tata Medical Center,Kolkata 700160,India [5]Department of Pathology,Dunedin School of Medicine,University of Otago,Dunedin 9054,New Zealand [6]School of Health Sciences and Technology,University of Petroleum and Energy Studies,Dehradun 248007,India

出　　处：《World Journal of Gastrointestinal Oncology》2023年第9期1505-1519,共15页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：Pancreatic cancer(PanCa)presents a catastrophic disease with poor overall survival at advanced stages,with immediate requirement of new and effective treatment options.Besides genetic mutations,epigenetic dysregulation of signaling pathway-associated enriched genes are considered as novel therapeutic target.Mechanisms beneath the deoxyribonucleic acid methylation and its utility in developing of epi-drugs in PanCa are under trails.Combinations of epigenetic medicines with conventional cytotoxic treatments or targeted therapy are promising options to improving the dismal response and survival rate of PanCa patients.Recent studies have identified potentially valid pathways that support the prediction that future PanCa clinical trials will include vigorous testing of epigenomic therapies.Epigenetics thus promises to generate a significant amount of new knowledge of biological and medical importance.Our review could identify various components of epigenetic mechanisms known to be involved in the initiation and development of pancreatic ductal adenocarcinoma and related precancerous lesions,and novel pharmacological strategies that target these components could potentially lead to breakthroughs.We aim to highlight the possibilities that exist and the potential therapeutic interventions.

关 键 词：Methylation driven pathways Pancreatic cancer methylation markers Signaling pathway targeted therapy PanCa enriched methylated pathway Pre-cancer methylated pathways 

分 类 号：R735.9[医药卫生—肿瘤]